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In this paper, the enantiomers of (±)-1, previously studied as α1 and 5-HT1A ligands, were prepared both by
resolution of the racemate and asymmetric synthesis. The enantiomeric purity and absolute configuration
were determined by means of HPLC and polarimetric analysis. Enantiomers were evaluated for in vitro
5-HT1A and α1 receptor affinity by binding and functional assays. Results indicate that the two enantiomers
are almost equally potent at 5-HT1A and α1 receptor systems and, contrary to WB 4101, the
stereoselectivity is poor. As further support to these experimental findings, molecular docking studies on
the two enantiomers of (±)-1 have been performed and a comparison with those obtained for 5-HT1A
potent agonist (R)-flesinoxan and α1d antagonist (S)-WB 4101 has been drawn.Introduction
The α1 adrenergic receptors (α1 adrenoceptors) play a key role
in the modulation of the activity of the sympathetic nervous
system, thus they represent a target for many therapeutic
agents. α1 adrenoceptors are divided into at least three sub-
types named α1a (α1A), α1b (α1B), and α1d (α1D), with upper
and lower cases indicating the native and recombinant recep-
tors, respectively.1,2 α1 antagonists have been used to treat
hypertension and they are considered the first-line therapy for
the treatment of lower urinary tract symptoms associated with
clinical benign prostatic hyperplasia.3 5-HT1A is, to date, one
of the most studied serotonin (5-HT) receptor subtypes and it
represents a target for neurological research and drug devel-
opment. It is generally accepted that 5-HT1A is involved in
anxiety and depression; recently, it has been suggested that
5-HT1A agonists have neuroprotective properties,
4 whereas
5-HT1A antagonists could be useful in the treatment of
Alzheimer's disease.5
5-HT1A and α1-adrenergic receptors belong to the
G-protein-coupled receptor (GPCR) superfamily and despite
their distinct pharmacology they show a substantial similarity(approximately 45% identity) in their transmembrane amino
acid sequence.6 As a consequence, a number of 5-HT1A ligands
bind to α1-adrenergic receptors with high affinity.
In our previous studies, we performed structure–activity
relationship (SAR) analysis on a series of compounds derived
from structural modifications of WB 4101, a prototype of the
well-known class of α1-adrenoceptor antagonists (benzo-
dioxanes).7,8 We have reported the discovery of the dioxolane
derivative (±)-1 (Fig. 1), and evaluated the binding to α1 and
5-HT1A receptors. It was found that (±)-1 is a selective antago-
nist, at least in functional studies, for the α1D subtype. How-
ever, it displays high affinity for the 5-HT1A receptor with
consequently no selectivity, compared to the α1-adrenergicmun., 2015, 6, 677–690 | 677
00135, (R)-flesinoxan, (S)-WB
Scheme 1 Reagents and conditions: i) a. Na2CO3, TsCl, H2O, 0–5 °C.
b. SOCl2, toluene, reflux; ii) Py, CH2Cl2, 0 °C to reflux followed by
chromatographic separation; iii) C2H5ONa, C2H5OH, reflux.
MedChemCommConcise Articlesystem. In an extension of this work, we thought that it
would be interesting to obtain the single enantiomers of
compound (±)-1 in order to evaluate the possible stereospe-
cific interaction and thus the relative contribution of these
enantiomers to the binding with the 5-HT1A and α1-adrener-
gic receptors. The 5-HT1A and α1-adrenergic receptors have,
in fact, demonstrated a considerable influence of chirality
in their interactions with ligands. Some examples are repre-
sented by the potent 5-HT1A antagonist WAY 100135, whose
affinity resides predominantly in the (S)-enantiomer, being
28 times more potent than the (R)-enantiomer9,10 or by the
5-HT1A potent agonist flesinoxan for which the (R)-enantiomer
is 10 times more potent than the (S)-enantiomer.11,12 More-
over, some studies on WB 4101 and some analogues have
demonstrated that the (S)-isomer is more potent than its (R)
counterpart at α1-adrenoceptor subtypes.
13,14
In addition, in order to rationalize the obtained results,
molecular docking studies on compounds (±)-1 were performed,
using the 5-HT1A and α1d homology models previously built
by us.15 Successively, the “in silico” predicted binding mode was
compared with that of the 5-HT1A potent agonist (R)-flesinoxan
and α1d antagonist (S)-WB 4101.
Results and discussion
Enantioseparation of (±)-1 and determination of the
optical purity
Enantioseparation is often feasible by fractional crystalliza-
tion: the reaction of a racemic acid or base with an optically
active base or acid gives a pair of diastereomeric salts which
can be separated through preferential precipitation. Our
attempts on fractional crystallization of (±)-1 in the presence of
ĲL)Ĳ+)-tartaric or ĲD)Ĳ−)-mandelic acid as resolving agents, how-
ever, were investigated with no success. Another commonly
used method for the resolution of racemates involves enantio-
separation of the optical isomers using semipreparative chiral
HPLC. Unfortunately, using a chiral semipreparative column
(Chiralcel OD), only a partial separation was achieved (Rs <1.5)
under several chromatographic conditions. Thus in order to
obtain enantiomerically pure (R)-1 and (S)-1, we focused on
the conversion of the enantiomers into diastereomers and
the subsequent separation of the diastereomeric mixture
by ordinary separation techniques, such as chromatography.
Racemate (±)-1 was prepared by N-alkylation of 2-phenoxy-
ethylamine with 4-chloromethyl-2,2-diphenyl-1,3-dioxolane
according to our previously published procedure.7 Resolu-
tion of (±)-1 was achieved by conversion of the two enan-
tiomers into their diastereomeric amides.13 (S)-Proline was
N-tosylated and then used as a chiral resolving agent after
activation of the carboxylic group into the corresponding acyl
chloride (3) (Scheme 1).16 Thus N-tosyl-ĲS)-prolyl chloride (3)
was allowed to react with the amino group of (±)-1 to give a
pair of diastereomeric amides, (2S,4S)-2 and Ĳ2S,4R)-2, which
were separated by flash chromatography on a silica gel column,
using cyclohexane/ethyl acetate 70/30 Ĳv/v) as the mobile
phase.678 | Med. Chem. Commun., 2015, 6, 677–690Collected fractions were analysed by HPLC, using a Speri-5
silica gel column (250 × 4.6 mm, 5 μm), mobile phase: cyclo-
hexane/ethyl acetate 70/30 Ĳv/v), flow rate: 1 ml min−1,
column temperature: 20 °C, injection volume: 5 μL; UV detec-
tion at 254 nm, and pooled. As shown in Fig. 2a, a good reso-
lution between the peaks of the two diastereomers, (2S,4S)-2
and Ĳ2S,4R)-2, was obtained in a short analysis time (tR =
9.9 min for the first eluted isomer and 13.4 min for the last
one; resolution (Rs) = 5.89; selectivity (α) = 1.34). In order to
determine the diastereomeric purity of the pooled fractions,
the diastereomeric excess (d.e.) was calculated from the inte-
grated peak areas of the two diastereomers. The resulting d.e.
was found to be >99% for both isomers (Fig. 2b, c).
The separated isomers were characterized by means of
HPLC, HR-MS and 1H and 13C NMR analysis. The 1H NMR
spectra of (2S,4S)-2 and (2S,4R)-2 showed very little differ-
ences (<0.01 ppm) with regard to the chemical shift values of
the protons bound to the proline chiral carbon and those of
the methyl group of the tosyl moiety. Moreover, the 1H-NMR
spectrum of a single isomer (2S,4S)-2 or (2S,4R)-2 results in a
mixture of two conformers, (E) and (Z), due to the restricted
rotation about the amide C–N bond, making the spectral
assignments quite difficult. The amide C–N bond in fact is
locked at room temperature as if it were a double bond
(Fig. 3). In particular, in the case of the first eluted isomer
Ĳ2S,4S)-2, the ĲZ) : ĲE) ratio was 1 : 0.8 while 1 : 0.3 was found
for the last eluted isomer Ĳ2S,4R)-2, as determined by NOESY
experiments (see below) (E–Z notation refers to Cahn–Ingold–
Prelog priority rules). The different ratios are probably due to
the steric hindrance of cis tosyl-proline and 2,2-diphenyl-1,3-
dioxolan-4yl-methyl groups. As the temperature increases, the
energy available is sufficient to overcome the rotational bar-
rier and allow the two conformers to interchange.This journal is © The Royal Society of Chemistry 2015
Fig. 2 HPLC analysis of a) the diastereomeric amides (2S,4S)-2 (tR = 9.9 min) and (2S,4R)-2 (tR = 13.4 min); b) first eluted isomer (less polar);
c) second eluted isomer (more polar). Solvent peak (tR = 2.59 min) and impurities are eluted between 3.0–3.5 min. Chromatographic conditions:
column: Speri-5 silica gel (250 × 4.6 mm, 5 μm); mobile phase: cyclohexane/ethyl acetate, 70/30 Ĳv/v); flow rate: 1 ml min−1; column temperature:
20 °C; injection volume: 5 μL; detection: UV at 254 nm.
Fig. 3 Representation of the two conformers of the diastereomeric amide (2S,4S)-2 observed in 1H-NMR experiments. Red arrows indicate the
observed positive NOE effect.
MedChemComm Concise ArticleIn correspondence with the coalescence temperature
(100 °C), the chemical shifts of the (E) and (Z) conformers
vary up to a mean value comprised between that of the twoThis journal is © The Royal Society of Chemistry 2015forms weighted by their abundance. Nuclear Overhauser
Effect Spectroscopy experiments (NOESY) were also carried
out to identify cross peaks originating from conformationalMed. Chem. Commun., 2015, 6, 677–690 | 679
MedChemCommConcise Articleexchange. In particular, for small molecules having long
correlation time, the phase of the peak can be used as
evidence: with the diagonal signal phased ‘down’, the chemical
exchange cross peak is also phased ‘down’, as observed for
the H4 and H5-dioxolane, and H2 proline ĲE)/ĲZ) protons.
Moreover, NOESY experiments have enabled us to assign the
ĲE)/ĲZ) configuration. In particular, the (Z) conformer showed
two cross peaks originating from the NOE effect (opposite
sign compared to the diagonal) between the H2-proline pro-
ton and both methylene groups of the phenoxyethyl chain;
this is not true for the (E) isomer. Conversely, the (E) con-
former showed a positive NOE effect between the H2-proline
and H4-dioxolane proton and between the H2-proline and
CH2–N proton, as depicted in Fig. 3 (red arrows). The same
correlations have been observed for the two conformers of
the diastereomeric amide (2S,4R)-2.
The separated diastereomers (2S,4S)-2 and (2S,4R)-2 were
then transformed into the corresponding enantiomers (S)-1
and (R)-1 by reaction with sodium ethoxide.16 To confirm
that racemization does not occur in the course of the reac-
tion, a certain amount of enantiomer was converted into the680 | Med. Chem. Commun., 2015, 6, 677–690
Scheme 2 Reagents and conditions: i) C2H5ONa, C2H5OH, reflux; ii) 3, Py,
Scheme 3 Reagents and conditions: i) Ĳ2R)-Ĳ−)-3-chloro-1,2-propanediol
toluene, reflux; ii) 2-phenoxy-ethylamine, 2-methoxy-ethanol, KI, reflux.
Table 1 Specific optical rotation [α]20D and [α]
20
436 of enantiomers ĲS)-Ĳ+)-1′ and
ĲR)-Ĳ−)-3-chloro-1,2-propanediol
Compounds [α]20D [α
ĲS)-Ĳ+)-1′ +0.044 +0
ĲR)-Ĳ−)-1′ −0.044 −0
ĲS)-Ĳ+)-1 +0.039 +0
ĲR)-Ĳ−)-1 −0.037 −0
ĲS)-Ĳ+)-3-chloro-1,2-propanediol*a +0.137 +0
ĲR)-Ĳ−)-3-chloro-1,2-propanediol*b −0.085 −0
*Standards employed to test the accuracy of the measurements.a 97% pu
ĲR)-Ĳ−)-1, CHCl3 was used as a solvent; for ĲS)-Ĳ+)-3-chloro-1,2-propanediolcorresponding amide of N-tosyl-ĲS)-proline (Scheme 2) and
HPLC analysis was carried out, using the same experimental
conditions mentioned in Fig. 2. For both epimers, racemiza-
tion was excluded since the diastereomeric excess was >99%
(data not shown).
Determination of the absolute configuration. The absolute
configuration of the two optical isomers (S)-1 and (R)-1,
obtained by resolution of the racemate (±)-1, was assigned
using a comparison of the optical rotation with the authentic
samples Ĳ+)-ĲS)-1′ and Ĳ−)-ĲR)-1′, which were prepared by asym-
metric synthesis, starting from the commercially available
chiral alcohols Ĳ−)-ĲR)-3-chloro-1,2-propanediol (e.e. 98%) and
Ĳ+)-ĲS)-3-chloro-1,2-propanediol (e.e. 97%), respectively, fol-
lowing the procedure previously reported for the synthesis
of racemate (±)-1 (Scheme 3).7 The conversion of the chloro
derivative (R)-4 into the corresponding amine Ĳ+)-ĲS)-1′ causes
the inversion of notation (R to S form and vice versa) due to
the priority changes around the stereocenter.
Table 1 illustrates the specific optical rotation of enantio-
mers (S)-1′ and (R)-1′, obtained from the asymmetric synthe-
sis, and the specific optical rotation of enantiomers (S)-1 andThis journal is © The Royal Society of Chemistry 2015
CH2Cl2, 0–5 °C to reflux.
, p-TSA, toluene, reflux; i*) Ĳ2S)-Ĳ+)-3-chloro-1,2-propanediol, p-TSA,
ĲR)-Ĳ−)-1′, ĲS)-Ĳ+)-1 and ĲR)-Ĳ−)-1, and ĲS)-Ĳ+)-3-chloro-1,2-propanediol and
]20436 [α]
20
D [α]
20
436 g ml
−1c
.107 +3.8 +9.4 0.011
.109 −3.7 −9.1 0.012
.096 +3.9 +9.6 0.010
.092 −3.7 −9.2 0.010
.275 +8.5 +16.9 0.016
.157 −8.5 −15.7 0.010
re. b 98% pure. c For enantiomers ĲS)-Ĳ+)-1′ and ĲR)-Ĳ−)-1′, ĲS)-Ĳ+)-1 and
and ĲR)-Ĳ−)-3-chloro-1,2-propanediol, ethanol was used as a solvent.
MedChemComm Concise Article(R)-1, obtained from the racemate (±)-1. Enantiomers (S)-1
and (R)-1 exhibit almost equal magnitude but opposite sign
of specific optical rotation ([α]20436 = +9.6 and −9.2, respectively),
in agreement with the theory of optical activity. Enantiomers
(S)-1 and (R)-1 showed a similar value of [α]20436 when compared
to the authentic samples (S)-1′ and (R)-1′ ([α]20436 = +9.4 and
−9.1, respectively). The specific rotation of the enantiomers
of 3-chloro-1,2-propanediol was calculated as evidence prov-
ing the accuracy of the measurements. The enantiomers
ĲS)-Ĳ+)-1 and ĲR)-Ĳ−)-1 were then treated with oxalic acid and
the resulting oxalate salts were tested for biological activity
on 5-HT1A and α1 receptors.
Structure–affinity and activity relationships
The pharmacological profile was initially evaluated by radioligand
binding assays. Table 2 lists the affinity constants (pKi) of
enantiomers (S)-1, (R)-1 and the racemate (±)-1 for the 5-HT1A
receptor and for three α1-adrenoceptor subtypes (α1a, α1b, α1d)
along with the 5-HT1A/α1 selectivities.
The R- and S-enantiomers and their racemate (±)-1 bind
preferentially to the 5-HT1A receptor than to the three α1
adrenergic subtypes with the R-form being the most selective
Ĳ5-HT1A/α1d = 8).
While in the case of WB 4101, the S-enantiomer displays
at least ten-fold higher 5-HT1A affinity than its corresponding
R-isomer,17 the affinities for 5-HT1A of the enantiomers of
(±)-1 are very similar, indicating the absence of stereospecific
interaction of the chiral carbon at the 4 position of the
1,3-dioxolane ring in the binding process with this receptor.
Both forms (S)-1 and (R)-1 behave as partial agonists for
5-HT1A, with potency values (pD2) of 7.45 and 6.85 and Emax
values of 65 and 50, respectively. Concerning the α1 receptor,
the affinities of the R-enantiomer for the three subtypes areThis journal is © The Royal Society of Chemistry 2015
Table 2 Affinity constants (pKi), potency (pD2) and selectivities of the racema
nant α1-adrenoceptor subtypes and 5-HT1A receptors
Compounds
(oxalate salts)
pKi [
35S]GTPγS pKi
5-HT1A pD2 Emax α1A α1B
(±)-1 8.45 8.80 24.4 7.43 7.20
(S)-1 8.42 6.85 50.0 6.90 6.94
(R)-1 8.52 7.45 65.3 7.52 7.10
(R)-WB 4101 7.39 7.95 7.14
(S)-WB 4101 8.61 9.39 8.24
pKi and pD2 values are the mean of 2–3 separate experiments performed i
Table 3 Antagonist potency in pKb or (pA2) ± SEM and selectivities of
α1-adrenoceptors in isolated rat prostatic vas deferens (α1A), spleen (α1B), and t
Compounds
(oxalate salts)
pKb or (pA2) ± SEM
α1A α1B α
(±)-1 6.16 ± 0.01 5.86 ± 0.13 (8
(S)-1 6.20 ± 0.03 6.14 ± 0.01 (7
(R)-1 6.67 ± 0.05 6.51 ± 0.04 (8
pA2 values were calculated at three different antagonist concentrations.
calculated at one or two concentrations.similar to that of the racemate (±)-1, indicating a small but
consistent preference for the α1d subtype. In terms of stereo-
selectivity, the S-isomer displays a lower affinity than the
R-isomer, in particular for α1a and α1b receptors, thus para-
lleling, although to a lesser extent, the finding obtained with
the enantiomers of WB 4101.13 Both (R)-1 and (S)-1 display
higher affinity for the α1d receptor subtype with selectivity of
approximately 2- and 4-fold for R and 9- and 8-fold for S over
α1a and α1b receptors, respectively.
The antagonist potency and subtype selectivity of com-
pound (±)-1 and its single enantiomers were also determined
for α1-adrenoceptors on different isolated tissues. Table 3
illustrates the pharmacological results obtained for functional
preparations such as prostatic vas deferens (α1A), spleen (α1B),
and thoracic aorta (α1D) of rat.
There is a correspondence between the binding and func-
tional affinities for α1-adrenoceptors; in fact, in both assays,
R- and S-enantiomers exhibit higher affinity towards α1D than
α1A and α1B.
Moreover, selectivity values for α1-adrenoceptor subtypes
are higher in functional with respect to the binding assays,
as a consequence of the lower affinities that the two isomers
display for α1A and α1B receptors in functional tests.
As shown in Tables II and III, the enantioselectivity ĲR/S)
to α1-adrenoceptors is quite low. In the case of the α1D recep-
tor subtype, for which (S)-1 and (R)-1 exhibit the highest
potency (pKb = 7.61 and 8.29, respectively), the R/S ratio is
only 5.Molecular modeling studies
In order to understand the binding mode of the enantiomers
of (±)-1 and to explain the low enantioselectivity, dockingMed. Chem. Commun., 2015, 6, 677–690 | 681
te (±)-1 and the resolved (S)-1 and (R)-1 enantiomers for human recombi-
5-HT1A/α1d α1a/α1b α1d/α1a α1d/α1bα1D
7.93 3 2 3 5
7.84 4 1 9 8
7.64 8 3 1 3
7.98
9.29
n duplicate. Values agreed within 10%.
the racemate (±)-1 and the resolved (S)-1 and (R)-1 enantiomers for
horacic aorta (α1D)
α1A/α1B α1D/α1A α1D/α1B1D
.20) ± 0.08 0.5 110 219
.61) ± 0.04 1 26 30
.29) ± 0.02 1 23 34
Each concentration was tested at least four times. pKb values were
MedChemCommConcise Articlestudies were performed on the 5-HT1A and α1d receptor
models.15
To assess if our models are able to stereoselectively dis-
criminate between the two enantiomers of (±)-1, the reference
5-HT1A agonist, flesinoxan and one of the most potent and
selective α1-adrenoreceptor antagonists WB 4101 were also
docked. These two compounds were chosen on the basis of
their high degree of enantioselectivity.10,12,18 According to
our calculations, the binding mode of (R)-flesinoxan into the
putative 5-HT1A binding site is characterized by a salt bridge
interaction between the protonated piperazine nitrogen and
the key residue D116 and two H-bond interactions of the
hydroxyl group with Y195 and S199 side-chain residues. In
addition, the benzamide portion and the benzodioxane
moiety display a number of π–π interactions with F19, Y96,
W102, F112 and with Y195, W358, F361, F362, respectively
(Fig. 4, the R enantiomer is depicted in cyan). On the con-
trary, (S)-flesinoxan shows only one H-bond contact with
S199, while no salt-bridge and hydrogen bond interactions
are detected with the key residue D116 and Y195, respectively
(Fig. 4, the S enantiomer is depicted in pink). These data are
in agreement with the fact that the activity of flesinoxan is
due to the (R)-enantiomer.12 Similarly to (R)-flesinoxan, (R)-1
displays a salt bridge interaction between the protonated
nitrogen atom and the D116 side-chain and an H-bond inter-
action between the dioxolane oxygen atom and the Y390
residue (Fig. 5, the R enantiomer is depicted in yellow). In
addition, the phenyl ring interacts with F19, Y96, W102 and682 | Med. Chem. Commun., 2015, 6, 677–690
Fig. 4 Selected docking pose of (R) and (S) flesinoxan into the 5-HT1A p
atom type (C atom, cyan and pink, respectively). The receptor residues lo
(C atom, light green). Hydrogen bond and salt-bridge contacts are reportedF112 residues, while the phenoxy group is widely engaged in
π–π stacking interactions with Y195, W358, F361 and F362.
As regards the (S)-1 enantiomer, the 1,3-dioxolane core is
moderately shifted with respect to (R)-1, causing the estab-
lishment of weaker interactions with the key residues D116
and Y390, thus resulting in a slight decrease of 5-HT1A affin-
ity. On the contrary, the phenyl and phenoxy rings are prop-
erly oriented towards F19, Y96, W102, F112 and Y195, W358,
F361, F362, respectively, as for (R)-1 (Fig. 5, the S enantiomer
is depicted in pink). However, the binding mode of (S)-1 is
quite similar to that observed for (R)-1. This is probably due
to the flexibility of the two molecules since they contain
several freely rotatable bonds. In conclusion, the docking
results of the two enantiomers of (±)-1 into the putative
5-HT1A binding site are in agreement with the poor stereo-
selectivity observed in the binding experiments.
The docking studies performed on the α1d receptor model
showed that (S)-WB 4101 is highly stabilized into the putative
binding site by a salt-bridge interaction with the D176 side-
chain and two H-bond contacts between the oxygen atom of
the methoxy group and the oxygen atom of the benzodioxane
core with Y254 and K385, respectively (Fig. 6, the S enantio-
mer is depicted in yellow). In addition, several π–π stacking
interactions are established between the benzodioxane moiety
and the phenoxy ring with W172, F384, F388 and Y254, F364,
F365, respectively. On the contrary, (R)-WB 4101 displays the
same salt-bridge and π–π stacking interactions as (S) but only
one H-bond contact with K385 (Fig. 6, the R enantiomer isThis journal is © The Royal Society of Chemistry 2015
utative binding site. The ligands are reported in stick and coloured by
cated 5 Å from the two ligands are shown and depicted by atom type
in red and blue, respectively.
Med. Chem. Commun., 2015, 6, 677–690 | 683This journal is © The Royal Society of Chemistry 2015
Fig. 5 Selected docking poses of (R)-1 and (S)-1 into the 5-HT1A putative binding site. The two ligands are reported in stick and coloured by atom
type (C atom, yellow and pink, respectively). The receptor residues located 5 Å from the ligands are shown and depicted by atom type (C atom,
light green). Hydrogen bond and salt-bridge contacts are reported in red and blue, respectively.
Fig. 6 Selected docking poses of (R)- and (S)-WB 4101 into the α1D putative binding site. The ligands are reported in stick and coloured by atom
type (C atom, green and yellow, respectively). The receptor residues located 5 Å from the agonists are shown and depicted by atom type (C atom,
grey). Hydrogen bond and salt-bridge contacts are reported in red and blue, respectively.
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MedChemCommConcise Articledepicted in green). The lack of the interaction with Y254 could
be an indication of the lower affinity of the (R)-enantiomer,
in agreement with the binding data (Table 2).
A first comparison between the binding mode of (±)WB
4101 and that of (S)-1 and (R)-1 shows that the replacement
of the 1,4-benzodioxane moiety with a 2,2-disubstituted
1,3-dioxolane turns around the docking pose of both enantio-
mers (Fig. 7). In particular, the phenoxyethylamine chain of
(S)- and (R)-1 is oriented towards a narrow pocket including
M156, W172, F384 and K385, while the 2,2-diphenyl-1,3-dioxolane
moiety is projected in a much more deep cavity delimited by
V177, Y254, S259, F364, F365 and L368. Thus, the stereogenic
centre of (±)-1 is located in a different cavity with respect to
(±)-WB 4101 and this seems to account for the loss of any sig-
nificant stereo interactions. As a matter of fact, (S)-1 displays
a salt bridge with the D176 side-chain, one H-bond between
the dioxolane oxygen atom and Y254 residue, and several π–π
interactions, while no H-bond contact has been detected with
K385 (Fig. 7, the S enantiomer is depicted in pink). This
might be the reason for the lower affinity of (S)-1 compared
to (S)-WB 4101 (α1d pKi = 7.84 and 9.29, respectively). On the
other hand, (R)-1 shows a salt-bridge and an H-bond interac-
tion with D176 and K385, respectively, while the dioxolane
scaffold is shifted with respect to (S)-1, guiding the oxygen
atom far away from any interaction with Y254 (Fig. 7, the R
enantiomer is depicted in orange). On the basis of these
results, it can be speculated that the low stereoselectivity684 | Med. Chem. Commun., 2015, 6, 677–690
Fig. 7 Selected docking pose of the (R)- and (S)-1 enantiomers into the α1D
atom type (C atom, orange and pink, respectively). The receptor residues
(C atom, grey). Hydrogen bond and salt-bridge contacts are reported in redobserved in the binding experiment for (R)-1 and (S)-1 could
be due to the fact that both enantiomers share the same type
of interaction and none of them is able to H-bond simulta-
neously with Y254 and K385.
Experimental
Chemistry
Material and methods. All reagents, solvents and other
chemicals were used as purchased from Sigma-Aldrich with-
out further purification unless otherwise specified. Solvents
used for salification and crystallization of the final compounds
were HPLC grade. All synthesized compounds were character-
ized by NMR, HR-MS and elemental analysis (C, H, N).
1H NMR spectra were recorded with a Bruker DPX 200 spectro-
meter operating at 200.13 MHz and a temperature between
270 and 370 K. 2D NMR spectra were recorded on a Bruker
Advance 400 WB working at frequencies of 400.13 and 100.61
for 1H and 13C, respectively, and at a temperature between
270 and 370 K. Chemical shifts (δ) are reported relative to
tetramethylsilane (TMS) as internal standard (s = singlet,
brs = broad singlet, d = doublet, dd = double doublet, t =
triplet, m = multiplet). 1H–1H correlation spectroscopy (COSY,
NOESY), 1H–13C heteronuclear multiple quantum coherence
(HMQC) and heteronuclear multiple bond connectivity (HMBC)
experiments were performed for determination of 1H–1H and
1H–13C correlations. HR-MS experiments were carried outThis journal is © The Royal Society of Chemistry 2015
putative binding site. The ligands are reported in stick and coloured by
located 5 Å from the agonists are shown and depicted by atom type
and blue, respectively.
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LC/MS - Agilent Technologies) equipped with an ion spray ioni-
zation source (ESI). MS (+) spectra were acquired by direct
infusion (5 ml min−1) of a solution containing the appropri-
ate sample oxalate salt (10 pmol ml−1), dissolved in 0.1%
acetic acid solution, with the mobile phase methanol/water
50 : 50, at the optimum ion voltage of 4800 V. Elemental analy-
sis was performed with an Elemental Analyser 1106 (Carlo
Erba Instruments, Italy). Analysis data are reported within
±0.4% of theoretical values. Optical rotations were recorded
on a Perkin Elmer 241 polarimeter at 436 nm and 589 nm.
Melting points were determined on a Büchi 510 capillary
melting point apparatus and were uncorrected. Reaction prog-
ress was monitored by TLC (silica gel 60, F254, Merck). Separa-
tions were performed on silica gel columns (Kiesegel 60,
0.040–0.630 mm, Merck) by flash chromatography or by using
the Biotage SP1 Purification System. Preparative TLC was car-
ried out on silica gel glass plates (silica gel 60, F254, 2 mm,
20 × 20 cm, Merck).
HPLC analysis of the diastereomers was carried out on a
1100 System (Agilent Technologies) consisting of a vacuum
degasser, a quaternary pump, an autosampler, a thermostated
column compartment and a diode array detector, using a
Speri-5 silica gel column (250 × 4.6 i.d. mm, 5 μm, Applied
Biosystems), with a mobile phase cyclohexane/ethyl acetate
70 : 30 Ĳv/v), at a flow rate of 1.0 mL min−1. The column was
thermostated at 20 °C. The sample injection volume was 5 μL.
The detection wavelength was set at 254 nm. The total analy-
sis time was 20 min.
Compound names were generated with MarvinSketch soft-
ware, version 5.10.1.
ĳ(2,2-diphenyl-1,3-dioxolan-4-yl)methyl]Ĳ2-phenoxyethyl)amine
(1). The compound was synthesized as previously reported.7
1.45 g (3.87 mmol), yield 75%, 1H-NMR (200 MHz, CDCl3):
δ = 1.67 (brs, 1H, NH), 2.83 (dd, J = 12.3, 4.8 Hz, 1H, CHa–NH),
2.93 (dd, J = 12.3, 6.8 Hz, 1H, CHb–NH), 3.03 (t, J = 5.3 Hz, 2H,
CH2–CH2–O–Ph), 3.84 (dd, J = 7.9, 6.3 Hz, 1H, H5a-dioxolane),
4.06 (t, J = 5.3 Hz, 2H, CH2–CH2–O–Ph), 4.09 (dd, J = 7.9, 7.0 Hz,
1H, H5b-dioxolane), 4.37 (m, 1H, H4-dioxolane), 6.90 (m, 2H,
H2/H6-phenoxy), 6.95 (m, 1H, H4-phenoxy), 7.24–7.38 (m, 8H,
H3/H5-phenoxy, H2/H6-diphenyl, H4-diphenyl), 7.47–7.56
(m, 4H, H3/H5-diphenyl).
The free amine was transformed into the corresponding
oxalate salt which was crystallized from methanol to give com-
pound (1), m.p. 189°–191 °C; 1H-NMR (200 MHz, DMSO): δ =
3.03 (dd, J = 12.0, 7.7 Hz, 1H, CHa–NH), 3.15 (dd, J = 12.0, 3.9
Hz, 1H, CHb–NH), 3.28 (t, J = 5.1 Hz, 2H, CH2–CH2–O–Ph),
3.95 (dd, J = 8.0, 6.3 Hz, 1H, H5a-dioxolane), 4.20 (dd, J = 8.0,
6.8 Hz, 1H, H5b-dioxolane), 4.17 (t, J = 5.1 Hz, 2H, CH2–CH2–
O–Ph), 4.40 (m, 1H, H4-dioxolane), 6.92–6.99 (m, 3H, H2/H6-
phenoxy, H4-phenoxy), 7.26–7.46 (m, 12H, H3/H5-phenoxy,
H2/H6-diphenyl, H4-diphenyl, H3/H5-diphenyl).
Anal. calcd. for C26H27O7N: C, 67.09; H, 5.85; N, 3.01.
Found: C, 67.35; H, 5.81; N, 3.11. HR-MS (ESI-Q-Tof): calc.
for C24H25O3N [M + H]
+ 375.1834; found 375.1839, Dev.
1.3 ppm.This journal is © The Royal Society of Chemistry 2015Ĳ2S)-1-Ĳ4-methylbenzenesulfonyl)pyrrolidine-2-carbonyl chlo-
ride (S)-3. To a solution of (S)-proline (1 g, 8.7 mmol) in 7.5 ml
of water was added Na2CO3 (1.70 g, 16.0 mmol) and then slowly
p-toluenesulfonyl chloride (2.00 g, 10.5 mmol) at 0 °C. The
reaction mixture was stirred at room temperature for 22 h.
1 N HCl was added until the solution was acidic and the
resulting mixture was taken up in ethyl acetate (4 × 15 ml). The
organic phase was dried over Na2SO4, filtered, and the
solvent evaporated. 1.82 g (6.8 mmol, 78% yield) of N-tosyl-
ĲS)-proline was obtained and used for the next step without
any further purification. N-tosyl-ĲS)-proline (1 g, 3.5 mmol)
was dissolved in 6 ml of toluene; to this solution was care-
fully added thionyl chloride (1.32 g, 11.1 mmol). The reaction
mixture was refluxed for 30 min. After removal of the solvent,
1.07 g (3.7 mmol, 98% yield) of (S)-3 was obtained and imme-
diately allowed to react in the next step without any further
purification.19 M.p. 56–57 °C; 1H-NMR (400 MHz, CDCl3): δ =
1.84–1.90 (m, 1H, CHa-4 proline), 1.92–2.05 (m, CHb-4, CHa-3
proline), 2.15–2.23 (m, 1H, CHb-3 proline), 2.48 (s, 3H, CH3
tosyl), 3.35–3.45 (m, 1H, CHa-5 proline), 3.50–3.56 (m, 1H,
CHb-5 proline), 4.65 (dd, J = 6.1, 7.9 Hz, 1H, CH-2 proline),
7.37 (d, J = 8.0 Hz, 2H, CH-3, CH-5 arom. tosyl), 7.78 ppm
(d, J = 8.0 Hz, 2H, CH-2, CH-6 arom. tosyl).
Ĳ2S)-N-ĳ(2,2-diphenyl-1,3-dioxolan-4-yl)methyl]-1-Ĳ4-
methylbenzenesulfonyl)-N-Ĳ2-phenoxyethyl)pyrrolidine-2-
carboxamide (2). To a solution of (±)-1 in CH2Cl2 was added
pyridine and a solution of 3 in CH2Cl2 at 0 °C. The reaction
mixture was warmed to RT and refluxed for 50 min. NaHCO3
was added, and the organic layer was separated and washed
with H2O, dried over Na2SO4 and concentrated under reduced
pressure. The residue was purified by flash chromatography
(cyclohexane/EtOAc 80 : 20) or preparative TLC (cyclohexane/
EtOAc 50 : 50) to yield the single diastereomer.
Ĳ2S)-N-{[Ĳ4S)-2,2-diphenyl-1,3-dioxolan-4-yl]methyl}-1-Ĳ4-
methylbenzenesulfonyl)-N-Ĳ2-phenoxyethyl)pyrrolidine-2-
carboxamide (2S,4S)-2. 0.38 g (0.6 mmol) of ĲS,S)-4, 21% yield.
(Z) conformer (56%).
1H-NMR (400 MHz) (CDCl3): δ = 1.74–1.88 (m, 1H, H4a
proline), 1.93–2.08 (m, 1H, H3a proline), 2.08–2.20 (m, 2H,
H4b proline, H3b proline), 2.42 (s, 3H, CH3 tosyl), 3.30 (dd,
J = 14.0, 7.5 Hz, 1H, CH2–N), 3.4–3.54 (m, 2H, H5 proline), 3,74
(m, 1H, N–CH2), 3.83 (dd, J = 8.2, 6.9 Hz, 1H, H5a-dioxolane),
4.03 (dd, J = 14.0, 3.6 Hz, 1H, CH2–N), 4,11 (m, 1H, H5b-
dioxolane), 4.32 (t, J = 4.5, 2H, CH2O–Ph), 4.35 (dd, J = 9.9,
4.1 Hz, 1H, N–CH2), 4.42 (m, 1H, H4 dioxolane), 5.05 (dd, J =
3.7, J = 7.7, 1H, H2 proline), 6.92 (m, 2H, H2/H6-phenoxy),
7.03 (m, 1H, H4-phenoxy), 7.26 (d, J = 8.2 Hz, 2H, H3/H5-tosyl),
7.26–7.39 (m, 8H, H3/H5-phenoxy, H2/H6 and H4-phenyl),
7.42–7.54 (m, 4H H3/H5-phenyl), 7.75 (d, J = 8.2 Hz, 2H,
H2/H6-tosyl).
13C-NMR (100 MHz) (CDCl3): δ = 21.55 (CH3-Tosyl), 24.88
(C4-proline), 31.42 (C3-proline), 48.65 (C5-proline), 49.0 (CH2–
CH2–O–Ph), 50.46 (CH2–N–CO), 57.53 (C2-proline), 65.83 (CH2–
CH2–O–Ph), 67.88 ĲC5-dioxolane), 75.67 ĲC4-dioxolane), 110.71
ĲC2-dioxolane), 114.51 (C2-phenoxy), 121.33 (C4-phenoxy), 126.12
(C4-phenyl), 127.45 (C2-tosyl), 128.16 (C2-phenyl), 129.50Med. Chem. Commun., 2015, 6, 677–690 | 685
MedChemCommConcise Article(C3-phenoxy), 129.55 (C3-phenyl), 129.63 (C3-tosyl), 136.16
(C1-tosyl), 143.58 (C4-tosyl), 158.36 (C1-phenoxy), 172.91 (CO–N).
(E) conformer (44%).
1H-NMR (400 MHz, CDCl3): δ = 1.47–1.58 (m, 2H, H3a
proline, H4a proline), 1.74–1.92 (m, 1H, H3b proline), 1.97–
2.01 (m, 1H, H4b proline), 2.42 (s, 3H, CH3 tosyl), 3.4–3.54
(m, 2H, H5 proline), 3.58 (dd, J = 15.3, 3.4 Hz, 1H, CH2–N),
3.70–3.86 (m, 2H, N–CH2), 4.02 (m, 1H, H5a-dioxolane), 4.13
(m, 1H, H5b-dioxolane), 4.19 (t, 4.9 Hz, 2H, CH2O–Ph), 4.21
(dd, J = 15.3, 8.9, 1H, CH2–N), 4.59 (m, 1H, H4 dioxolane),
4.83 (dd, J = 4.1, 7.8 Hz, 1H, H2-proline), 6.86 (m, 2H, H2/
H6-phenoxy), 6.99 (m, 1H, H4-phenoxy), 7.23 (d, J = 8.2 Hz,
2H, H3/H5-tosyl), 7.27–7.38 (m, 8H, H3/H5-phenoxy, H2/H6
and H4-phenyl), 7.42–7.55 (m, 4H, H3/H5-phenyl), 7.72 (d,
J 8.2 Hz, 2H, H2/H6-tosyl).
13C-NMR (100 MHz) (CDCl3): δ = 21.55 (CH3-tosyl), 24.90
(C4-proline), 31.52 (C3-proline), 48.56 (C5-proline), 49.0 (CH2–
CH2–O–Ph), 50.46 (CH2–N–CO), 57.43 (C2-proline), 65.83 (CH2–
CH2–O–Ph), 68.08 ĲC5-dioxolane), 75.70 ĲC4-dioxolane), 109.99
ĲC2-dioxolane), 114.54 (C2-phenoxy), 121.05 (C4-phenoxy), 126.17
(C4-phenyl), 127.32 (C2-tosyl), 128.14 (C2-phenyl), 129.50 (C3-
phenoxy), 129.58 (C3-phenyl), 129.63 (C3-tosyl), 136.16 (C1-tosyl),
143.58 (C4-tosyl), 158.36 (C1-phenoxy), 172.87 (CO–N).
Ĳ2S)-N-{[Ĳ4R)-2,2-diphenyl-1,3-dioxolan-4-yl]methyl}-1-Ĳ4-
methylbenzenesulfonyl)-N-Ĳ2-phenoxyethyl)pyrrolidine-2-
carboxamide (2S,4R)-2. 0.45 g (0.7 mmol) of ĲS,R)-4, 24% yield.
(Z) conformer (77%).
1H-NMR (400 MHz) (CDCl3): δ = 1.80–1.91 (m, 1H, H4a
proline), 1.92–1.98 (m, 1H, H3a proline), 2.03–2.20 (m, 2H,
H4b proline, H3b proline), 2.40 (s, 3H, CH3 tosyl), 3.40 (dd,
J = 14.0, 7.5 Hz, 1H, CH2–N), 3.42–3.54 (m, 2H, H5 proline),
3,80–3.91 (m, 1H, N–CH2), 3.81 (dd, J = 8.3, 6.9 Hz, 1H,
H5a-dioxolane), 3.94 (dd, J = 14.0, 7.5 Hz, 1H, CH2–N), 4,08
(dd, J = 8.3, 6.9 Hz, 1H, H5b-dioxolane), 4.16 (t, J = 5.2, 2H,
CH2O–Ph), 4.23–4.31 (m, 1H, N–CH2), 4.42 (m, 1H, H4 dioxo-
lane), 5.05 (dd, J = 3.7, J = 7.9, 1H, H2 proline), 6.91 (m, 2H,
H2/H6-phenoxy), 7.02 (m, 1H, H4-phenoxy), 7.17 (d, J =
8.0 Hz, 2H, H3/H5-tosyl), 7.27–7.41 (m, 8H, H3/H5-phenoxy,
H2/H6 and H4-phenyl), 7.51–7.59 (m, 4H, H3/H5-phenyl),
7.74 (d, J 8.25 Hz, 2H, H2/H6-tosyl).
13C-NMR (100 MHz) (CDCl3): δ = 21.51 (CH3-tosyl), 24.92
(C4-proline), 31.46 (C3-proline), 48.46 (C5-proline), 49.18 (CH2–
CH2–O–Ph), 50.46 (CH2–N–CO), 57.47 (C2-proline), 65.64 (CH2–
CH2–O–Ph), 68.01 ĲC5-dioxolane), 76.21 ĲC4-dioxolane), 109.96
ĲC2-dioxolane), 114.46 (C2/C6-phenoxy), 121.36 (C4-phenoxy),
126.06 (C3/C5-phenyl), 127.36 (C2-tosyl), 128.08 (C2/C6-phenyl),
128.30 (C4-phenyl), 129.52 (C3-tosyl), 129.65 (C3/C5-phenoxy),
136.36 (C1-tosyl), 143.24 (C4-tosyl), 158.31 (C1-phenoxy), 173.08
(CO–N).
(E) conformer (23%).
1H-NMR (400 MHz) (CDCl3): δ = 1.77–1.91 (m, 2H, H3a
proline, H4a proline), 1.92–2.0 (m, 1H, H3b proline), 2.03–
2.20 (m, 1H, H4b proline), 2.41 (s, 3H, CH3 tosyl), 3.42–3.54
(m, 2H, H5 proline), 3.75 (dd, J = 15.7, 6.9 Hz, 1H, CH2–N),
3.80–3.91 (m, 2H, N–CH2), 3.92 (m, 1H, H5a-dioxolane), 4.04
(dd, J = 15.7, 4.0 Hz, 1H, CH2–N), 4.07 (m, 2H, CH2O–Ph),4.22686 | Med. Chem. Commun., 2015, 6, 677–690(m, 1H, H5b dioxolane), 4.50 (m, 1H, H4-dioxolane),4.84 (dd,
J = 4.0, 8.0 Hz, 1H, H2-proline), 6.86 (m, 2H, H2/H6-phenoxy),
6.99 (m, 1H, H4-phenoxy), 7.19 (d, J = 8.0 Hz, 2H, H3/H5-tosyl),
7.27–7.41 (m, 8H, H3/H5-phenoxy, H2/H6 and H4-phenyl),
7.51–7.59 (m, 4H, H3/H5-phenyl), 7.72 (d, J 8.0 Hz, 2H, H2/
H6-tosyl).
13C-NMR (100 MHz) (CDCl3): δ = 21.55 (CH3-tosyl), 24.86
(C4-proline), 31.11 (C3-proline), 48.43 (C5-proline), 49.21 (CH2–
CH2–O–Ph), 50.46 (CH2–N–CO), 57.51 (C2-proline), 65.65 (CH2–
CH2–O–Ph), 67.90 ĲC5-dioxolane), 76.30 ĲC4-dioxolane), 110.02
ĲC2-dioxolane), 114.50 (C2/C6-phenoxy), 121.01 (C4-phenoxy),
125.90 (C3/C5-phenyl), 127.36 (C2-tosyl), 128.08 (C2/C6-phenyl),
128.30 (C4-phenyl), 129.52 (C3-tosyl), 129.65 (C3/C5-phenoxy),
136.36 (C1-tosyl), 143.22 (C4-tosyl), 158.31 (C1-phenoxy), 173.08
(CO–N).
{[Ĳ4S)-2,2-diphenyl-1,3-dioxolan-4-yl]methyl} Ĳ2-phenoxyethyl)amine
(S)-1. (2S,4S)-2 was added to a 2 N solution of freshly pre-
pared sodium ethoxide. The mixture was heated under reflux
for 2 h. The solvent was evaporated and the residue was dissolved
in H2O and extracted three times with CHCl3. The organic phase
was washed with brine, dried over Na2SO4 and the solvent
removed under vacuum. The product was isolated without
any further purification. 0.06 g (0.2 mmol) of (S)-1, 90% yield.
1H-NMR (400 MHz, CDCl3): δ = 2.09 (brs, 1H, NH), 2.89
(dd, J = 12.3, 4.5 Hz, 1H, CHa–NH), 2.97 (dd, J = 12.3, 7.1 Hz,
1H, CHb–NH), 3.09 (t, J = 5.1 Hz, 2H, CH2–CH2–O–Ph), 3.91 ( dd,
J = 8.0, 6.2 Hz, 1H, H5a-dioxolane), 4.11 (t, J = 5.1 Hz, 2H,
CH2–CH2–O–Ph), 4.14 ( dd, J = 8.0, 7.0 Hz, 1H, H5b-dioxolane),
4.42 (m, 1H, H4-dioxolane), 6.95 (m, 2H, H2/H6-phenoxy),
7.00 (m, 1H, H4-phenoxy), 7.29–7.40 (m, 8H, H3/H5-phenoxy,
H2/H6-diphenyl, H4-diphenyl), 7.51–7.60 (m, 4H, H3/H5-diphenyl).
13C-NMR (100 MHz, CDCl3): δ = 48.95 ĲCH2–CH2–O–Ph),
52.36 (1C, CH2–NH), 67.07 ĲCH2–CH2–O–Ph), 68.19 ĲC5-dioxolane),
76.17 ĲC4-dioxolane), 109.97 ĲC2-dioxolane), 114.60 (C2/C6-
phenoxy), 120.91 (C4-phenoxy), 126.16 ĲC3/C5-diphenyl), 128.06
ĲC4-diphenyl), 128.10 ĲC2/C6-diphenyl), 129.19 (C3/C5-phenoxy),
142.28 ĲC1-diphenyl), 158.80 (C1-phenoxy). [α]D = +9.6° (0.01 g ml
−1
in CHC13).
The free amine (S)-1 (0.26 g, 0.70 mmol) was dissolved in
diethyl ether and treated with 1.0 eq. of oxalic acid to give the
corresponding oxalate salt which was crystallized from metha-
nol to give: 0.09 g (0.2 mmol), 43% yield; mp: 190°–192 °C.
1H-NMR (400 MHz, DMSO): δ = 3.13 (dd, J = 12.7, 7.9 Hz,
1H, CHa–NH), 3.25 (dd, J = 12.7, 3.6 Hz , 1H, CHb–NH), 3.38
(m, 2H, CH2–CH2–O–Ph), 3.85 ( dd, J = 8.1, 6.7 Hz, 1H, C5a-
dioxolane), 4.09 ( dd, J = 8.1, 7.1 Hz, 1H, C5a-dioxolane), 4.23
(t, J = 4.5 Hz, 2H, CH2–CH2–O–Ph), 4.47 (m, 1H, H4-dioxolane),
6.93–7.03 (m, 3H, H2/H6-phenoxy, H4-phenoxy), 7.27–7.43
(m, 8H, H3/H5-phenoxy, H2/H6-diphenyl, H4-diphenyl), 7.43–
7.50 (m, 4H, H3/H5-diphenyl).
13C-NMR (100 MHz, DMSO): δ = 47.17 ĲCH2–CH2–O–Ph),
50.17 (1C, CH2–NH), 64.25 ĲCH2–CH2–O–Ph), 67.97 ĲC5-dioxolane),
73.38 ĲC4-dioxolane), 110.25 ĲC2-dioxolane), 115.08 (2C, C2/
C6-phenoxy), 121.60 (C4-phenoxy), 126.35 (4C, C3/C5-diphenyl),
128.67 (2C, C4-diphenyl), 128.70 (4C, C2/C6-diphenyl), 130.03
(2C, C3/C5-phenoxy), 142.34 ĲC1-diphenyl), 158.33 (C1-phenoxy).This journal is © The Royal Society of Chemistry 2015
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Found: C, 67.29; H, 5.87; N, 3.10.
HR-MS (ESI-Q-Tof): calc. for C24H25NO3 [M + H]
+ 375.1834;
found 375.1827, dev. 1.9 ppm.
{[Ĳ4R)-2,2-diphenyl-1,3-dioxolan-4-yl]methyl} Ĳ2-phenoxyethyl)amine
(R)-1. The compound was synthesized from (S,R)-2 following
the procedure described for (S)-1; 0.06 g (0.2 mmol) of (R)-1,
89% yield.
1H-NMR (400 MHz, CDCl3) identical to that of (S)-1; [α]D =
−9.2° (0.01 g ml−1 in CHC13).
The free amine (R)-1 (0.16 g, 0.40 mmol) was dissolved in
diethyl ether and treated with 1.0 eq. of oxalic acid to give
the corresponding oxalate salt which was crystallized from
methanol to give: 0.05 g (0.1 mmol), 38% yield; mp 189–191 °C;
1H NMR (400 MHz, DMSO) identical to that of (S)-1.
Anal. calcd. for C26H27NO7: C, 67.09; H, 5.85; N, 3.01.
Found: C, 67.35; H, 5.81; N, 3.11.
HR-MS (ESI-Q-Tof): calc. for C24H25NO3 [M + H]
+ 375.1834;
found 375.1839, dev. 1.3 ppm.
Ĳ4R)-4-Ĳchloromethyl)-2,2-diphenyl-1,3-dioxolane (R)-4. The
compound was synthesized as previously reported starting
from Ĳ2R)-Ĳ+)-3-chloro-1,2-propanediol.7 0.67 g (2.4 mmol) of
(4R)-4, 82% yield.
1H-NMR (200 MHz, CDCl3): δ = 3.48 (dd, J = 10.9, 7.9 Hz,
1H, CHa–Cl); 3.69 (dd, J = 10.9, 4.8 Hz, 1H, CHb–Cl); 4.02
(dd, J = 8.5, 5.2 Hz, 1H, H5a-dioxolane); 4.14 (dd, J = 8.5,
6.5 Hz, 1H, H5b-dioxolane); 4.44 (m, 1H, H4-dioxolane);
7.25–7.39 (m, 6H, H2/H6-diphenyl, H4-diphenyl); 7.46–7.57
(m, 4H, H3/H5-diphenyl). [α]D = +37.3° (0.01 g ml
−1 in
CH2C12).
Ĳ4S)-4-Ĳchloromethyl)-2,2-diphenyl-1,3-dioxolane (S)-4. The
compound was synthesized as previously reported starting
from ĲS)-Ĳ−)-3-chloro-1,2-propanediol.7 0.67 g (2.4 mmol) of
(4S)-4, 82% yield.
1H-NMR (200 MHz, CDCl3) identical to that of (R)-4; [α]D =
−37.8° (0.01 g ml−1 in CH2C12).
{[Ĳ4S)-2,2-diphenyl-1,3-dioxolan-4-yl]methyl}Ĳ2-phenoxyethyl)-
amine (S)-5. The compound was synthesized from (R)-4 as
previously reported.7 0.52 g (1.4 mmol), 58% yield. 1H-NMR
(400 MHz, CDCl3) and
13C-NMR (100 MHz, CDCl3) identical
to those of (S)-1; [α]D = +9.4° (0.011 g ml
−1 in CHC13).
The free amine (0.16 g, 0.4 mmol) was dissolved in diethyl
ether and treated with 1.0 eq. of oxalic acid to give the corre-
sponding oxalate salt which was crystallized from methanol
to give: 0.09 g (0.19 mmol), 45% yield; mp 190–192 °C; 1H
NMR (400 MHz, DMSO) and 13C-NMR (100 MHz, DMSO)
identical to those of (S)-1.
Anal. calcd. for C24H25NO3: C, 76.77; H, 6.71; N, 3.73.
Found: C, 76.71; H, 6.72; N, 3.69. HRMS-ESI: calc. for C24H26NO3
[M + H] + 376.2383; found 376.2382.
{[Ĳ4R)-2,2-diphenyl-1,3-dioxolan-4-yl]methyl}Ĳ2-phenoxyethyl)-
amine (R)-5. The compound was synthesized from (S)-4 as
previously reported.7 0.58 g (1.6 mmol), 64% yield; [α]D =
−9.1° (0.011 g ml−1 in CHC13).
1H-NMR (400 MHz, DMSO) and 13C-NMR (100 MHz, CDCl3)
identical to those of (S)-5.This journal is © The Royal Society of Chemistry 2015The free amine (0.16 g, 0.40 mmol) was dissolved in
diethyl ether and treated with 1.0 eq. of oxalic acid to give
the corresponding oxalate salt which was crystallized from
methanol to give: 0.05 g (0.1 mmol), 38% yield; mp 189–191 °C;
1H NMR (400 MHz, DMSO) and 13C-NMR (100 MHz, DMSO)
identical to those of (S)-5.
Anal. calcd. for C24H25NO3: C, 76.77; H, 6.71; N, 3.73.
Found: C, 76.84; H, 6.76; N, 3.75. HRMS-ESI: calc. for
C24H26NO3 [M + H] + 376.2383; found 376.2385.Pharmacology
The compounds were tested as oxalate salts. The purity of the
salts was confirmed by elemental analysis and the values
obtained are within ±0.4% of the calculated ones. The exact
mass of the salts was confirmed by HPLC-QTOF measure-
ment. The HPLC-UV purity was found to be >98%. All experi-
ments were performed in compliance with the relevant laws
and institutional guidelines.Functional antagonism in isolated tissues
Male Wistar rats (275–300 g) were killed by cervical disloca-
tion, and the organs required were isolated, freed from
adhering connective tissues, and set up rapidly under a suit-
able resting tension in 20 mL of organ baths containing phys-
iological salt solution kept at 37 °C and aerated with 5%
CO2–95% O2 at pH 7.4. Concentration–response curves were
constructed by cumulative addition of the agonist. The con-
centration of the agonist in the organ bath was increased
approximately 3-fold at each step, with each addition being
made only after the response to the previous addition had
attained a maximal level and remained steady. Contractions
were recorded by means of a force displacement transducer
connected to the Mac Lab system PowerLab/800 and to a
polygraph channel recorder (Gemini). In addition, parallel
experiments in which tissues did not receive any antagonist
were run in order to check any variation in sensitivity.Vas deferens prostatic portion
This tissue was used to assess the antagonism toward α1A
adrenoceptors.20 Prostatic portions of 2 cm length were
mounted under 0.5 g of tension at 37 °C in Tyrode's solution
of the following composition (mM): NaCl, 130; KCl, 1; CaCl2,
1.8; MgCl2, 0.89; NaH2PO4, 0.42; NaHCO3, 25; glucose, 5.6.
cocaine hydrochloride (0.1 μM), to prevent the neuronal
uptake of (−)-noradrenaline. The preparations were equilibrated
for 60 min by washing every 15 min. After the equilibration
period, tissues were primed twice by addition of 10 μM nor-
adrenaline. After another washing and equilibration period
of 60 min, a noradrenaline concentration–response curve
was constructed (basal response). The antagonist was equili-
brated for 30 min before construction of a new concentration–
response curve to the agonist. (−)-Noradrenaline solutions
contained 0.05% Na2S2O5 to prevent oxidation.Med. Chem. Commun., 2015, 6, 677–690 | 687
MedChemCommConcise ArticleSpleen
This tissue was used to assess the antagonism toward α1B
adrenoceptors.21 The spleen was removed and bisected longi-
tudinally into two strips, which were suspended in tissue
baths containing Krebs solution of the following composition
(mM): NaCl, 120; KCl, 4.7; CaCl2, 2.5; MgSO4, 1.5; KH2PO4,
1.2; NaHCO3, glucose, 11; K2EDTA, 0.01. Propranolol hydro-
chloride (4 μM) was added to block β-adrenoceptors. The
spleen strips were placed under 1 g of resting tension and
equilibrated for 2 h. The cumulative concentration–response
curves to phenylephrine were measured isometrically and
obtained at 30 min intervals, the first one being discarded
and the second taken as a control. The antagonist was
allowed to equilibrate for 30 min before constructing a new
concentration–response curve to the agonist.
Aorta
This tissue was used to assess the antagonism toward α1D
adrenoceptors.22 Thoracic aorta was cleaned from extraneous
connective tissues and placed in Krebs solution of the follow-
ing composition (mM): NaCl, 118.4; KCl, 4.7; CaCl2, 1.9; MgSO4,
1.2; NaH2PO4, 1.2; NaHCO3, 25; glucose, 11.7; K2EDTA, 0.01.
Cocaine hydrochloride (0.1 μM) and propranolol hydrochloride
(4 μM) were added to prevent the neuronal uptake of
(−)-noradrenaline and to block β-adrenoceptors, respectively.
Two helicoidal strips (15 mm × 3 mm) were cut from each
aorta, beginning from the end that is most proximal to the
heart. The endothelium was removed by rubbing with filter
paper. The absence of acetylcholine (100 μM) induced relax-
ation in preparations contracted with (−)-noradrenaline (1 μM)
was taken as an indicator that the vessels were denuded suc-
cessfully. Vascular strips were then tied with surgical thread
and suspended in a jacketed tissue bath containing Tyrode's
solution. Strip contractions were measured isometrically.
After at least a 2 h equilibration period under an optimal tension
of 1 g, cumulative (−)-noradrenaline concentration–response curves
were recorded at 1 h intervals, the first two being discarded
and the third one taken as control. The antagonist was equi-
librated with the tissue for 30 min before the generation
of the fourth cumulative concentration–response curve to
(−)-noradrenaline. (−)-Noradrenaline solutions contained 0.05%
K2EDTA in 0.9% NaCl to prevent oxidation.
Radioligand binding assay at human recombinant 5-HT1A
receptors and α1 adrenoceptor subtypes
A human cell line (HeLa) stably transfected with genomic
clone G-21 coding for the human 5-HT1A serotoninergic recep-
tor was used. Cells were grown as monolayers in Dulbecco's
modified Eagle's medium supplemented with 10% fetal calf
serum and gentamycin (100 μg mL−1) under 5% CO2 at 37 °C.
Cells were detached from the growth flask at 95% confluence
by a cell scraper and were lysed in ice-cold Tris (5 mM) and
EDTA buffer (5 mM, pH 7.4). Homogenates were centrifuged
for 20 min at 40000 g, and pellets were resuspended in a small
volume of ice-cold Tris/EDTA buffer (above) and immediately688 | Med. Chem. Commun., 2015, 6, 677–690frozen and stored at 70 °C until use. On the day of the experi-
ment, cell membranes (80–90 μg of protein) were resuspended
in binding buffer (50 mM Tris, 2.5 mM MgCl2, and 10 mM
pargyline, pH 7.4). Membranes were incubated in a final
volume of 0.32 mL for 30 min at 30 °C with 1 nM ĳ3H]8-OH-
DPAT, in the absence or presence of various concentrations
of the competing drugs (1 pM to 1 μM); each experimental
condition was performed in triplicate. Nonspecific binding
was determined in the presence of 10 μM 5-HT. Binding to
recombinant human α1 adrenoceptor subtypes was performed
in membranes from Chinese hamster ovary (CHO) cells trans-
fected by electroporation with DNA expressing the gene
encoding each α1 adrenoceptor subtype. Cloning and stable
expression of the human α1 adrenoceptor genes were performed
as described.23 CHO cell membranes (70 μg of protein) were
incubated in 50 mM Tris (pH 7.4) with 0.1–0.4 nM [3H]prazosin,
in a final volume of 0.32 mL for 30 min at 25 °C, in the absence
or presence of competing drugs (1 pM to 1 μM). Nonspecific
binding was determined in the presence of 10 μM Tamsulosin.
The incubation was stopped by addition of ice-cold Tris buffer
and rapid filtration through Unifilter B filters (Perkin-Elmer)
using a Filtermate cell harvester (Packard), and the radioactivity
retained on the filters was determined by TopCount, Perkin-
Elmer liquid scintillation counting at 90% efficiency.
[35S]GTPγS binding assay
The effects of the various compounds tested on [35S]GTPγS
binding in HeLa cells expressing the recombinant human
5-HT1A receptor were evaluated according to the method of
Stanton and Beer24 with minor modifications. Stimulation
experiments: cell membranes (50–70 μg of protein) were
resuspended in a buffer containing 20 mM HEPES, 3 mM
MgSO4, and 120 mM NaCl (pH 7.4). The membranes were
incubated with 30 μM GDP and various concentrations (from
0.1 nM to 10 μM) of test drugs or 8-OH-DPAT (reference
curve) for 20 min at 30 °C in a final volume of 0.5 mL.
Samples were transferred to ice, [35S]GTPγS (200 pM) was
added, and samples were incubated for another 30 min at
30 °C. The pre-incubation with both agonist and antagonist,
before initiating the [35S]GTPγS binding, ensures that the ago-
nist and antagonist are at equilibrium. Nonspecific binding
was determined in the presence of 10 μM GTPγS. Incubation
was stopped by the addition of ice-cold HEPES buffer and
rapid filtration on Unifilter B filters (Perkin Elmer) using a
Filtermate cell harvester (Packard). The filters were washed
with ice-cold Hepes buffer, and the radioactivity retained on
the filters was determined by TopCount, Perkin Elmer liquid
scintillation counting at 90% efficiency.
Data analysis
Binding data were analyzed using the nonlinear curve-fitting
program GraphPad (Prism for Windows, version 5.04).
Scatchard plots were linear for all preparations. None of the
pseudo-Hill coefficients (nH) were significantly different from
unity (p > 0.05). Equilibrium dissociation constants (Ki) wereThis journal is © The Royal Society of Chemistry 2015
MedChemComm Concise Articlederived from the Cheng–Prusoff equation Ki = IC50/ĲL/Kd),
where L and Kd are the concentration and the equilibrium
dissociation constant of the radioligand. pKi values are the
mean of 2–3 separate experiments performed in duplicate.25
Stimulation of [35S]GTPγS binding induced by the compounds
tested was expressed as the percent increase in binding above
the basal value, with the maximal stimulation observed with
8-OH-DPAT taken as 100%. The concentration–response
curves of the agonistic activity were analyzed by GraphPad as
reported above.26 The maximum percentage of stimulation of
[35S]GTPγS binding (Emax) achieved for each drug, and the
concentration required to obtain 50% of Emax (pD2 = −log10
[EC50]) were evaluated.
In functional studies, responses were expressed as a
percentage of the maximal contraction observed in the ago-
nist concentration–response curves, taken as a control,
which were analyzed by pharmacological computer programs.
pA2 values were calculated according to the method of
Arunlakshana and Schild from the dose ratios at EC50 values
of the agonists calculated at three different antagonist con-
centrations. Each concentration was tested at least four
times, and the Schild plots were constrained to a slope of −1
as required by theory. pKb values were calculated according
to the method of van Rossum at one or two concentrations.27Docking analysis by molecular modeling
The ĲR/S)-flesinoxan, ĲR/S)-WB 4101 and the (R)-1 and (S)-1
enantiomers were built, parameterised (Gasteiger–Huckel
method) and energy minimised within MOE using MMFF94
forcefield.28 For all compounds, the protonated form was
considered for the in silico analyses. In the absence of crystal-
lographic data for the 5-HT1A receptor, the theoretical model
of the human 5-HT1A previously built by us has been used for
docking simulations.15 An alpha1D theoretical model has been
built starting from the X-ray structure of the β2-adrenoreceptor
(pdb code 2RH1), by applying the homology modeling strategy
already described by us for the 5-HT1A receptor model. Briefly,
since most of the key residues characteristic of GPCRs are con-
served in the α1D-adrenoreceptor, an α1D homology model has
been generated, starting from the X-ray structure of human
β2-adrenoreceptor (PDB code: 2RH1; resolution = 2.40 Å), in
complex with a partial inverse agonist compound.29 The
amino acid sequence of the α1D-adrenoreceptor (P25100) was
retrieved from the SWISSPROT database30 while the three-
dimensional structure coordinate file of the GPCR template
was obtained from the Protein Data Bank.31 The amino acid
sequences of α1D TM helices were aligned with the corre-
sponding residues of 2RH1, on the basis of the Blosum62
matrix (MOE software). The connecting loops were constructed
by the loop search method implemented in MOE. The energy
minimization was carried out by 1000 steps of steepest descent
followed by conjugate gradient minimization until the rms gra-
dient of the potential energy was less than 0.1 kcal mol−1 Å−1.
The assessment of the final obtained model was performed
using Ramachandran plots, generated within MOE.This journal is © The Royal Society of Chemistry 2015Docking studies were subsequently performed, according
to the following protocol. The binding site of the ligand in
the 5-HT1A receptor was determined starting from the fact
that, for the ligand activity, formation of the salt bridge
between the protonated piperazine nitrogen on the ligand
and Asp116 is necessary.32–34
On the other hand, the α1d-adrenoreceptor binding site
has been determined by taking especially into account the
conserved residues highlighted by a comparison with the
β2-adrenoreceptor and 5-HT1A binding site.
Each isomer was docked into the putative ligand binding
site by means of the Surflex docking module implemented in
Sybyl-X1.0.35 Then, for all the compounds, the best docking
geometries (selected on the basis of the SurFlex scoring func-
tions) were refined by ligand–receptor complex energy mini-
mization (CHARMM27) by means of the MOE software. To ver-
ify the reliability of the derived docking poses, the obtained
ligand/receptor complexes were further investigated by docking
calculations (10 run), using MOE-Dock (Genetic algorithm;
applied on the poses already located into the putative 5-HT1A
or α1d-adrenoreceptor). The conformers showing lower energy
scoring functions and rmsd values (with respect to the starting
poses) were selected as the most stable and discussed here.
Conclusions
In this paper, the enantiomers of (±)-1 were prepared and
evaluated for in vitro 5-HT1A and α1 receptor affinity by binding
and functional assays. Results indicate that the two enantio-
mers are almost equally potent at 5-HT1A and α1 receptor sys-
tems. In silico results were consistent with the pharmacological
findings as they indicated that the binding modes of the two
enantiomers were almost identical.
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